Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

by rvvadmin | Sep 16, 2020 | 2020

TORONTO, Sept. 16, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the...

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

by rvvadmin | Sep 2, 2020 | 2020

TORONTO, Sept. 02, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the...

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

by rvvadmin | Aug 31, 2020 | 2020

TORONTO, Aug. 31, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the...

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

by rvvadmin | Aug 26, 2020 | 2020

Revive to also explore FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19 TORONTO, Aug. 26, 2020- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and...

Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

by rvvadmin | Aug 19, 2020 | 2020

TORONTO, Aug. 19, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that following...